# US 2025/0147028 A1 · Chromogranin a as a marker for bladder cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0147028 A1
- Document ID: US20250147028A1
- Status: Published application
- Kind: A1
- Application number: 19/017,937
- Filed: 2025-01-13
- Published: 2025-05-08
- Earliest claimed: 2016-03-09
- Assignees: Cezanne S.A.S.
- Applicants: CéZanne S.A.S.
- Inventors: Bénédicte JARDIN-WATELET; Nicolas BOURGOIN; Tibor SZARVAS
- Web page: https://patentgrep.com/patent/US20250147028A1

## CPC

- G01N 33/57585: {involving compounds identifiable in body fluids}
- A61N 5/00: Radiation therapy (ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00)
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present invention relates to the use of Chromogranin A (CgA) as a marker (particularly a prognostic marker) for bladder cancer, particularly non-neuroendocrine bladder cancer and preferably urothelial carcinoma. In particular, CgA can be used as a marker in an in vitro assay for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma). The invention further pertains to a method for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma) in a subject, comprising the step of determining the level of CgA and optionally MMP7 in a sample of a bodily fluid of said subject.

## Claims

### Claim 1

An in vitro method for predicting disease-specific survival in a patient diagnosed with non-neuroendocrine bladder cancer comprising:
measuring a concentration level of chromogranin A protein in a sample of blood, serum, or plasma taken from the patient before and/or after surgical treatment of the non-neuroendocrine bladder cancer;
wherein a concentration level greater than a predetermined threshold range of about 130 ng/ml to 160 ng/ml is indicative of reduced disease-specific survival.

### Claim 2 (depends on 1)

The method of claim 1, wherein the concentration level is measured before or after trans-urethral resection of the bladder tumor (TURBT), or before or after radical cystectomy (RCE).

### Claim 3 (depends on 1)

The method of claim 1, wherein the non-neuroendocrine bladder cancer is urothelial carcinoma.
